<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00384059</url>
  </required_header>
  <id_info>
    <org_study_id>6096A1-007</org_study_id>
    <nct_id>NCT00384059</nct_id>
  </id_info>
  <brief_title>Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants</brief_title>
  <official_title>A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United Kingdom</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability and immunogenicity of a
      13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when given
      concomitantly with routine paediatric vaccines in the United Kingdom.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving a Meningococcal C Serum Bactericidal Assay (SBA) Titer ≥1:8 and Predefined Antibody Levels for Pertussis and Haemophilus Influenzae Type b in 13vPnC Group Relative to 7vPnC Group After the 2-dose Infant Series.</measure>
    <time_frame>One month after infant series dose 2 (5 months of age)</time_frame>
    <description>Percentage of participants achieving a meningococcal C SBA serum antibody titer ≥1:8 and predefined antibody threshold levels with the corresponding 95% CI for concomitant antigens polyribosylribitol phosphate (PRP) in haemophilus influenzae type b [Hib](≥0.15 μg/mL or ≥ 1.0 μg/mL), pertussis toxoid [PT], filamentous haemagglutinin, pertactin [FHA], and pertactin (PRN) (≥5 Elisa Units EU/mL) and fimbrial agglutinogens [FIM] (≥2.2 EU/mL) are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titer (GMT) of Meningococcal C Antigen as Measured by SBA in 13vPnC Group Relative to 7vPnC Group After the 2-dose Infant Series</measure>
    <time_frame>one month after infant series dose 2 (5 months of age)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Antibody Concentration of Haemophilus Influenzae Type b (Hib) Polyribosylribitol Phosphate (PRP) as Measured by Enzyme-linked Immunosorbent Assay (ELISA) in 13vPnC Group Relative to 7vPnC Group After the 2-dose Infant Series</measure>
    <time_frame>one month after infant series dose 2 (5 months of age)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Antibody Concentration of Pertusis Filamentous Haemagglutinin (FHA), Pertussis Toxoid (PT), Pertactin (PRN), and Fimbrial Agglutinogens (FIM) as Measured by ELISA in 13vPnC Group Relative to 7vPnC Group After the 2-dose Infant Series</measure>
    <time_frame>one month after infant series dose 2 (5 months of age)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants in the 13vPnC Group Achieving a Serotype-specific IgG Antibody Concentration ≥0.35 µg/mL Measured 1 Month After the 2-dose Infant Series, Before and After the Toddler Dose</measure>
    <time_frame>one month after infant series dose 2 (5 months of age), before and after toddler dose (12 months of age)</time_frame>
    <description>Percentages of participants achieving WHO predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Antibody Concentration in 13vPnC Group After the 2-dose Infant Series, Before and After the Toddler Dose.</measure>
    <time_frame>one month after infant series dose 2 (5 months of age) and before and after toddler dose (12 months of age)</time_frame>
    <description>Antibody concentration/geometric mean concentration (GMC) as measured by ELISA for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented with corresponding 2-sided 95% CI.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving an SBA Titer ≥1:8 for Meningococcal C in 13vPnC Group Relative to 7vPnC Group Before and After the Toddler Dose.</measure>
    <time_frame>one month after the toddler dose (13 months of age)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a Predefined Antibody Level for Haemophilus Influenzae Type b in the 13vPnC Group Relative to the 7vPnC Group After the Toddler Dose.</measure>
    <time_frame>one month after toddler dose (13 months of age)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Antibody Concentration for Haemophilus Influenzae Type b PRP in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose.</measure>
    <time_frame>one month after toddler dose (13 months of age)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer (GMT) of Meningococcal C Antigen as Measured by SBA in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose</measure>
    <time_frame>one month after toddler dose (13 months of age)</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of Participants Reporting Pre-Specified Local Reactions</measure>
    <time_frame>During the 4-day period after each dose</time_frame>
    <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Participants may be represented in more than 1 category.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants Reporting Pre-Specified Systemic Events</measure>
    <time_frame>During the 4-day period after each dose</time_frame>
    <description>Systemic events (fever ≥ 38 degrees Celsius [C] but ≤ 39 C, fever &gt;39 C but ≤ 40 C, fever &gt; 40 C, decreased appetite, irritability, increased sleep, decreased sleep, use of medication (Meds) to prevent symptoms, and use of medication to treat symptoms) were collected using an electronic diary; percentage of participants with each event was evaluated.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">286</enrollment>
  <condition>Vaccines, Pneumococcal</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>13-valent pneumococcal vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>7-valent pneumococcal vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13-valent Pneumococcal Conjugate Vaccine</intervention_name>
    <description>Single 0.5 mL dose given at 2, 3, 4, and 12 months of age</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>7vPnC</intervention_name>
    <description>Single 0.5 mL dose given at 2, 3, 4 and 12 months of age</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pediacel</intervention_name>
    <description>concommitant vaccine, both at arm 1 and at arm 2, at 2 months, 3 months and 4 months of age</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NeisVac-C</intervention_name>
    <description>concomittant vaccine, both at arm 1 and at arm 2, at 2 months and 4 months of age</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Menitorix</intervention_name>
    <description>concomitant vaccine, both at arm 1 and at arm 2, at 12 months of age</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged 2 months (42 to 98 days) at the time of enrollment.

          2. Available for entire study period and whose parent(s)/legal guardian(s) could be
             reached by telephone.

          3. Healthy infant, as determined by medical history, physical examination, and judgment
             of the investigator.

          4. Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures
             during study participation.

        Exclusion Criteria:

          1. Previous vaccination with licensed or investigational pneumococcal vaccine.

          2. Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or
             meningococcal vaccines.

          3. A previous anaphylactic reaction to any vaccine or vaccine-related component.

          4. Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis,
             polio, pneumococcal conjugate, or meningococcal conjugate vaccines.

          5. Bleeding diathesis or condition associated with prolonged bleeding time that would
             contraindicate intramuscular injection.

          6. Known or suspected immune deficiency or suppression.

          7. History of culture-proven invasive disease caused by S pneumoniae, Neisseria
             meningitidis, or Hib.

          8. Major known congenital malformation or serious chronic disorder.

          9. Significant neurological disorder or history of seizure, including febrile seizure, or
             significant stable or evolving disorders, such as cerebral palsy, encephalopathy,
             hydrocephalus, or other significant disorders. This did not include resolving
             syndromes due to birth trauma such as Erb palsy.

         10. Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and
             monoclonal antibodies; eg, Synagis®).

         11. Participation in another investigational trial. Participation in purely observational
             studies was acceptable.

         12. Infant who was a direct descendant (eg, child or grandchild) of the study site
             personnel.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>42 Days</minimum_age>
    <maximum_age>98 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Trial Manager</last_name>
    <role>Principal Investigator</role>
    <affiliation>For UK/Great Britian, ukmedinfo@wyeth.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Atherstone</city>
        <zip>CV9 1EU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangor</city>
        <zip>BT19 1NB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bristol</city>
        <zip>BS2 8AE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Co Antrim</city>
        <zip>BT41 3AE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coventry</city>
        <zip>CV6 4DD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ely</city>
        <zip>CB7 4HF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>SW17 ORE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plymouth</city>
        <zip>PL5 3JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Weston-Super-Mare</city>
        <zip>BS22 6AJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2006</study_first_submitted>
  <study_first_submitted_qc>October 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2006</study_first_posted>
  <results_first_submitted>March 26, 2010</results_first_submitted>
  <results_first_submitted_qc>July 6, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 15, 2012</results_first_posted>
  <disposition_first_submitted>February 26, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>September 30, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 1, 2009</disposition_first_posted>
  <last_update_submitted>January 22, 2013</last_update_submitted>
  <last_update_submitted_qc>January 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited in the United Kingdom (UK) from October 2006 to June 2007.</recruitment_details>
      <pre_assignment_details>Participants were enrolled into the study according to inclusion/exclusion criteria without a screening period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>13vPnC</title>
          <description>Participants received one single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with meningococcal C-tetanus toxoid conjugate vaccine (NeisVac-C) and a combined diphtheria, tetanus, five component acellular pertussis (DT5aP), inactivated poliomyelitis (IPV) and haemophilus influenzae type b (Hib) conjugate vaccine (Pediacel) at the 2- and 4-month visits (infant series). Pediacel was administered without study vaccine at 3-month visit. Participants recieved one single 0.5 mL dose of 13vPnC coadministered with Haemophilus Influenzae Type b (Hib) and Meningococcal C Vaccine (Menitorix) at the 12-month visit (toddler dose).</description>
        </group>
        <group group_id="P2">
          <title>7vPnC</title>
          <description>Participants received one single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with meningococcal C-tetanus toxoid conjugate vaccine (NeisVac-C) and a combined diphtheria, tetanus, five component acellular pertussis (DT5aP), inactivated poliomyelitis (IPV) and haemophilus influenzae type b (Hib) conjugate vaccine (Pediacel) at the 2- and 4-month visits (infant series). Pediacel was administered without study vaccine at 3-month visit. Participants recieved one single 0.5 mL dose of 7vPnC coadministered with Haemophilus Influenzae Type b (Hib) and Meningococcal C Vaccine (Menitorix) at the 12-month visit (toddler dose).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Infant Series</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="141"/>
                <participants group_id="P2" count="145"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 1</title>
              <participants_list>
                <participants group_id="P1" count="139"/>
                <participants group_id="P2" count="139"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 2</title>
              <participants_list>
                <participants group_id="P1" count="136"/>
                <participants group_id="P2" count="135"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="135"/>
                <participants group_id="P2" count="132"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not consented</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>After Infant Series</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="135"/>
                <participants group_id="P2" count="132"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="131"/>
                <participants group_id="P2" count="122"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed to Return</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Toddler Dose</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="131"/>
                <participants group_id="P2" count="122"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="130"/>
                <participants group_id="P2" count="120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed to return</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>13vPnC</title>
          <description>Participants received one single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with meningococcal C-tetanus toxoid conjugate vaccine (NeisVac-C) and a combined diphtheria, tetanus, five component acellular pertussis (DT5aP), inactivated poliomyelitis (IPV) and haemophilus influenzae type b (Hib) conjugate vaccine (Pediacel) at the 2- and 4-month visits (infant series). Pediacel was administered without study vaccine at 3-month visit. Participants recieved one single 0.5 mL dose of 13vPnC coadministered with Haemophilus Influenzae Type b (Hib) and Meningococcal C Vaccine (Menitorix) at the 12-month visit (toddler dose).</description>
        </group>
        <group group_id="B2">
          <title>7vPnC</title>
          <description>Participants received one single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with meningococcal C-tetanus toxoid conjugate vaccine (NeisVac-C) and a combined diphtheria, tetanus, five component acellular pertussis (DT5aP), inactivated poliomyelitis (IPV) and haemophilus influenzae type b (Hib) conjugate vaccine (Pediacel) at the 2- and 4-month visits (infant series). Pediacel was administered without study vaccine at 3-month visit. Participants recieved one single 0.5 mL dose of 7vPnC coadministered with Haemophilus Influenzae Type b (Hib) and Meningococcal C Vaccine (Menitorix) at the 12-month visit (toddler dose).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="120"/>
            <count group_id="B2" value="118"/>
            <count group_id="B3" value="238"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.1" spread="0.3"/>
                    <measurement group_id="B2" value="2.1" spread="0.2"/>
                    <measurement group_id="B3" value="2.1" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving a Meningococcal C Serum Bactericidal Assay (SBA) Titer ≥1:8 and Predefined Antibody Levels for Pertussis and Haemophilus Influenzae Type b in 13vPnC Group Relative to 7vPnC Group After the 2-dose Infant Series.</title>
        <description>Percentage of participants achieving a meningococcal C SBA serum antibody titer ≥1:8 and predefined antibody threshold levels with the corresponding 95% CI for concomitant antigens polyribosylribitol phosphate (PRP) in haemophilus influenzae type b [Hib](≥0.15 μg/mL or ≥ 1.0 μg/mL), pertussis toxoid [PT], filamentous haemagglutinin, pertactin [FHA], and pertactin (PRN) (≥5 Elisa Units EU/mL) and fimbrial agglutinogens [FIM] (≥2.2 EU/mL) are presented.</description>
        <time_frame>One month after infant series dose 2 (5 months of age)</time_frame>
        <population>Evaluable immunogenicity (per protocol) population consisting of eligible participants who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations; (n) = number of participants with a determinate postinfant series antibody concentration to the given concomitant antigen.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>Participants received one single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with meningococcal C-tetanus toxoid conjugate vaccine (NeisVac-C) and a combined diphtheria, tetanus, five component acellular pertussis (DT5aP), inactivated poliomyelitis (IPV) and haemophilus influenzae type b (Hib) conjugate vaccine (Pediacel) at the 2- and 4-month visits (infant series). Pediacel was administered without study vaccine at 3-month visit. Participants recieved one single 0.5 mL dose of 13vPnC coadministered with Haemophilus Influenzae Type b (Hib) and Meningococcal C Vaccine (Menitorix) at the 12-month visit (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>Participants received one single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with meningococcal C-tetanus toxoid conjugate vaccine (NeisVac-C) and a combined diphtheria, tetanus, five component acellular pertussis (DT5aP), inactivated poliomyelitis (IPV) and haemophilus influenzae type b (Hib) conjugate vaccine (Pediacel) at the 2- and 4-month visits (infant series). Pediacel was administered without study vaccine at 3-month visit. Participants recieved one single 0.5 mL dose of 7vPnC coadministered with Haemophilus Influenzae Type b (Hib) and Meningococcal C Vaccine (Menitorix) at the 12-month visit (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Meningococcal C Serum Bactericidal Assay (SBA) Titer ≥1:8 and Predefined Antibody Levels for Pertussis and Haemophilus Influenzae Type b in 13vPnC Group Relative to 7vPnC Group After the 2-dose Infant Series.</title>
          <description>Percentage of participants achieving a meningococcal C SBA serum antibody titer ≥1:8 and predefined antibody threshold levels with the corresponding 95% CI for concomitant antigens polyribosylribitol phosphate (PRP) in haemophilus influenzae type b [Hib](≥0.15 μg/mL or ≥ 1.0 μg/mL), pertussis toxoid [PT], filamentous haemagglutinin, pertactin [FHA], and pertactin (PRN) (≥5 Elisa Units EU/mL) and fimbrial agglutinogens [FIM] (≥2.2 EU/mL) are presented.</description>
          <population>Evaluable immunogenicity (per protocol) population consisting of eligible participants who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations; (n) = number of participants with a determinate postinfant series antibody concentration to the given concomitant antigen.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Meningococcal C ≥ 1:8 titer (n=120,118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.2" lower_limit="95.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.2" lower_limit="95.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hib (PRP) ≥ 0.15 μg/mL (n=114,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.5" lower_limit="91.3" upper_limit="99.0"/>
                    <measurement group_id="O2" value="98.0" lower_limit="93.1" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hib (PRP) ≥ 1.0 μg/mL (n=114,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.1" lower_limit="77.2" upper_limit="91.1"/>
                    <measurement group_id="O2" value="89.2" lower_limit="81.5" upper_limit="94.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis PT ≥ 5 EU/mL (n=119,112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="96.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="96.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis PT ≥ 17 EU/mL (n=119,112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.6" lower_limit="91.6" upper_limit="99.1"/>
                    <measurement group_id="O2" value="95.5" lower_limit="89.9" upper_limit="98.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis FHA ≥ 5 EU/mL (n=119,113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="96.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="96.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis FHA ≥ 7.82 EU/mL (n=119,113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="96.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="96.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis FHA ≥ 20 EU/mL (n=119,113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.1" lower_limit="88.3" upper_limit="97.6"/>
                    <measurement group_id="O2" value="95.6" lower_limit="90.0" upper_limit="98.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis PRN ≥ 5 EU/mL (n=119,113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="96.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="96.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis PRN ≥ 15 EU/mL (n=119,113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.4" lower_limit="86.1" upper_limit="96.5"/>
                    <measurement group_id="O2" value="95.6" lower_limit="90.0" upper_limit="98.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis FIM ≥ 2.2 EU/mL (n=119,113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="96.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="97.3" lower_limit="92.4" upper_limit="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis FIM ≥ 5 EU/mL (n=119,113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.5" lower_limit="92.8" upper_limit="99.5"/>
                    <measurement group_id="O2" value="96.5" lower_limit="91.2" upper_limit="99.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Meningococcal C the difference in percentage between the two groups (13vPnC - 7vPnC) at 1:8 titer was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.8</ci_lower_limit>
            <ci_upper_limit>3.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Haemophilus influenzae type b the difference in percentage between the two groups (13vPnC - 7vPnC) at 0.15 µg/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC – 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-7.1</ci_lower_limit>
            <ci_upper_limit>3.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Haemophilus influenzae type b the difference in percentage between the two groups (13vPnC - 7vPnC) at 1.0 µg/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC – 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-4.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-13.4</ci_lower_limit>
            <ci_upper_limit>5.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Pertussis PT the difference in percentage between the two groups (13vPnC - 7vPnC) at 5 EU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC – 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.2</ci_lower_limit>
            <ci_upper_limit>3.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Pertussis PT the difference in percentage between the two groups (13vPnC - 7vPnC) at 17 EU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC – 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.5</ci_lower_limit>
            <ci_upper_limit>7.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Pertussis FHA the difference in percentage between the two groups (13vPnC - 7vPnC) at 5 EU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC – 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.2</ci_lower_limit>
            <ci_upper_limit>3.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Pertussis FHA the difference in percentage between the two groups (13vPnC - 7vPnC) at 7.82 EU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC – 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.2</ci_lower_limit>
            <ci_upper_limit>3.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Pertussis FHA the difference in percentage between the two groups (13vPnC - 7vPnC) at 20 EU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC – 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-7.9</ci_lower_limit>
            <ci_upper_limit>4.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Pertussis PRN the difference in percentage between the two groups (13vPnC - 7vPnC) at 5 EU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC – 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.2</ci_lower_limit>
            <ci_upper_limit>3.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Pertussis PRN the difference in percentage between the two groups (13vPnC - 7vPnC) at 15 EU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC – 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-3.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-10.0</ci_lower_limit>
            <ci_upper_limit>3.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Pertussis FIM the difference in percentage between the two groups (13vPnC - 7vPnC) at 2.2 EU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC – 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>2.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>7.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Pertussis FIM the difference in percentage between the two groups (13vPnC - 7vPnC) at 5 EU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC – 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.1</ci_lower_limit>
            <ci_upper_limit>6.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving an SBA Titer ≥1:8 for Meningococcal C in 13vPnC Group Relative to 7vPnC Group Before and After the Toddler Dose.</title>
        <time_frame>one month after the toddler dose (13 months of age)</time_frame>
        <population>Evaluable immunogenicity (per protocol) population consisting of eligible participants who adhered to protocol requirements, had valid and determinate assay results, and had no other major protocol violations; (n)= number of participants with a determinate posttoddler dose antibody concentration to the given concomitant antigen.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Before Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C at the 2- and 4-month visits, Pediacel at the 2-, 3-, and 4-month visits.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC Before Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with NeisVac-C at the 2- and 4-month visits, Pediacel at the 2-, 3-, and 4-month visits.</description>
          </group>
          <group group_id="O3">
            <title>13vPnC After Toddler Dose</title>
            <description>Participants received Menitorix at the 12-month visit.</description>
          </group>
          <group group_id="O4">
            <title>7vPnC After Toddler Dose</title>
            <description>Participants received Menitorix at the 12-month visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving an SBA Titer ≥1:8 for Meningococcal C in 13vPnC Group Relative to 7vPnC Group Before and After the Toddler Dose.</title>
          <population>Evaluable immunogenicity (per protocol) population consisting of eligible participants who adhered to protocol requirements, had valid and determinate assay results, and had no other major protocol violations; (n)= number of participants with a determinate posttoddler dose antibody concentration to the given concomitant antigen.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="109"/>
                <count group_id="O4" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.1" lower_limit="34.3" upper_limit="54.3"/>
                    <measurement group_id="O2" value="49.5" lower_limit="38.9" upper_limit="60.0"/>
                    <measurement group_id="O3" value="91.7" lower_limit="84.9" upper_limit="96.2"/>
                    <measurement group_id="O4" value="91.8" lower_limit="84.5" upper_limit="96.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Meningococcal C the difference in percentage between the two groups (13vPnC - 7vPnC) at 1:8 titer was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>-5.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-19.7</ci_lower_limit>
            <ci_upper_limit>8.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Meningococcal C the difference in percentage between the two groups (13vPnC - 7vPnC) at 1:8 titer was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-8.0</ci_lower_limit>
            <ci_upper_limit>8.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a Predefined Antibody Level for Haemophilus Influenzae Type b in the 13vPnC Group Relative to the 7vPnC Group After the Toddler Dose.</title>
        <time_frame>one month after toddler dose (13 months of age)</time_frame>
        <population>Evaluable immunogenicity (per protocol) population consisting of eligible participants who adhered to protocol requirements, had valid and determinate assay results, and had no other major protocol violations; (N) = number of participants with a determinate posttoddler dose antibody concentration to the given concomitant antigen.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>Participants received one single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with meningococcal C-tetanus toxoid conjugate vaccine (NeisVac-C) and a combined diphtheria, tetanus, five component acellular pertussis (DT5aP), inactivated poliomyelitis (IPV) and haemophilus influenzae type b (Hib) conjugate vaccine (Pediacel) at the 2- and 4-month visits (infant series). Pediacel was administered without study vaccine at 3-month visit. Participants recieved one single 0.5 mL dose of 13vPnC coadministered with Haemophilus Influenzae Type b (Hib) and Meningococcal C Vaccine (Menitorix) at the 12-month visit (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>Participants received one single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with meningococcal C-tetanus toxoid conjugate vaccine (NeisVac-C) and a combined diphtheria, tetanus, five component acellular pertussis (DT5aP), inactivated poliomyelitis (IPV) and haemophilus influenzae type b (Hib) conjugate vaccine (Pediacel) at the 2- and 4-month visits (infant series). Pediacel was administered without study vaccine at 3-month visit. Participants recieved one single 0.5 mL dose of 7vPnC coadministered with Haemophilus Influenzae Type b (Hib) and Meningococcal C Vaccine (Menitorix) at the 12-month visit (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Predefined Antibody Level for Haemophilus Influenzae Type b in the 13vPnC Group Relative to the 7vPnC Group After the Toddler Dose.</title>
          <population>Evaluable immunogenicity (per protocol) population consisting of eligible participants who adhered to protocol requirements, had valid and determinate assay results, and had no other major protocol violations; (N) = number of participants with a determinate posttoddler dose antibody concentration to the given concomitant antigen.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hib (PRP) ≥0.15 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="96.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="96.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hib (PRP)≥1.0 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.0" lower_limit="94.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="96.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Haemophilus influenzae type b the difference in percentage between the two groups (13vPnC - 7vPnC) at 0.15 µg/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.5</ci_lower_limit>
            <ci_upper_limit>3.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Haemophilus influenzae type b the difference in percentage between the two groups (13vPnC - 7vPnC) at 1.0 µg/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>-1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.3</ci_lower_limit>
            <ci_upper_limit>2.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer (GMT) of Meningococcal C Antigen as Measured by SBA in 13vPnC Group Relative to 7vPnC Group After the 2-dose Infant Series</title>
        <time_frame>one month after infant series dose 2 (5 months of age)</time_frame>
        <population>Evaluable immunogenicity (per protocol) population consisting of eligible participants who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations;(N) = number of participants with a determinate antibody concentration/titer for the specified concomitant antigen.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>Participants received one single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with meningococcal C-tetanus toxoid conjugate vaccine (NeisVac-C) and a combined diphtheria, tetanus, five component acellular pertussis (DT5aP), inactivated poliomyelitis (IPV) and haemophilus influenzae type b (Hib) conjugate vaccine (Pediacel) at the 2- and 4-month visits (infant series). Pediacel was administered without study vaccine at 3-month visit. Participants recieved one single 0.5 mL dose of 13vPnC coadministered with Haemophilus Influenzae Type b (Hib) and Meningococcal C Vaccine (Menitorix) at the 12-month visit (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>Participants received one single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with meningococcal C-tetanus toxoid conjugate vaccine (NeisVac-C) and a combined diphtheria, tetanus, five component acellular pertussis (DT5aP), inactivated poliomyelitis (IPV) and haemophilus influenzae type b (Hib) conjugate vaccine (Pediacel) at the 2- and 4-month visits (infant series). Pediacel was administered without study vaccine at 3-month visit. Participants recieved one single 0.5 mL dose of 7vPnC coadministered with Haemophilus Influenzae Type b (Hib) and Meningococcal C Vaccine (Menitorix) at the 12-month visit (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) of Meningococcal C Antigen as Measured by SBA in 13vPnC Group Relative to 7vPnC Group After the 2-dose Infant Series</title>
          <population>Evaluable immunogenicity (per protocol) population consisting of eligible participants who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations;(N) = number of participants with a determinate antibody concentration/titer for the specified concomitant antigen.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="306.20" lower_limit="251.21" upper_limit="373.22"/>
                    <measurement group_id="O2" value="345.42" lower_limit="287.91" upper_limit="414.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Meningococcal C the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for the concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Antibody Concentration of Haemophilus Influenzae Type b (Hib) Polyribosylribitol Phosphate (PRP) as Measured by Enzyme-linked Immunosorbent Assay (ELISA) in 13vPnC Group Relative to 7vPnC Group After the 2-dose Infant Series</title>
        <time_frame>one month after infant series dose 2 (5 months of age)</time_frame>
        <population>Evaluable immunogenicity (per protocol) population consisting of eligible participants who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations;(N) = number of participants with a determinate antibody concentration/titer for the specified concomitant antigen.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>Participants received one single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with meningococcal C-tetanus toxoid conjugate vaccine (NeisVac-C) and a combined diphtheria, tetanus, five component acellular pertussis (DT5aP), inactivated poliomyelitis (IPV) and haemophilus influenzae type b (Hib) conjugate vaccine (Pediacel) at the 2- and 4-month visits (infant series). Pediacel was administered without study vaccine at 3-month visit. Participants recieved one single 0.5 mL dose of 13vPnC coadministered with Haemophilus Influenzae Type b (Hib) and Meningococcal C Vaccine (Menitorix) at the 12-month visit (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>Participants received one single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with meningococcal C-tetanus toxoid conjugate vaccine (NeisVac-C) and a combined diphtheria, tetanus, five component acellular pertussis (DT5aP), inactivated poliomyelitis (IPV) and haemophilus influenzae type b (Hib) conjugate vaccine (Pediacel) at the 2- and 4-month visits (infant series). Pediacel was administered without study vaccine at 3-month visit. Participants recieved one single 0.5 mL dose of 7vPnC coadministered with Haemophilus Influenzae Type b (Hib) and Meningococcal C Vaccine (Menitorix) at the 12-month visit (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Concentration of Haemophilus Influenzae Type b (Hib) Polyribosylribitol Phosphate (PRP) as Measured by Enzyme-linked Immunosorbent Assay (ELISA) in 13vPnC Group Relative to 7vPnC Group After the 2-dose Infant Series</title>
          <population>Evaluable immunogenicity (per protocol) population consisting of eligible participants who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations;(N) = number of participants with a determinate antibody concentration/titer for the specified concomitant antigen.</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.40" lower_limit="2.65" upper_limit="4.37"/>
                    <measurement group_id="O2" value="4.44" lower_limit="3.50" upper_limit="5.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Haemophilus influenzae type b the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for the concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Antibody Concentration of Pertusis Filamentous Haemagglutinin (FHA), Pertussis Toxoid (PT), Pertactin (PRN), and Fimbrial Agglutinogens (FIM) as Measured by ELISA in 13vPnC Group Relative to 7vPnC Group After the 2-dose Infant Series</title>
        <time_frame>one month after infant series dose 2 (5 months of age)</time_frame>
        <population>Evaluable immunogenicity (per protocol) population consisting of eligible participants who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations;(n) = number of participants with a determinate antibody concentration/titer for the specified concomitant antigen.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>Participants received one single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with meningococcal C-tetanus toxoid conjugate vaccine (NeisVac-C) and a combined diphtheria, tetanus, five component acellular pertussis (DT5aP), inactivated poliomyelitis (IPV) and haemophilus influenzae type b (Hib) conjugate vaccine (Pediacel) at the 2- and 4-month visits (infant series). Pediacel was administered without study vaccine at 3-month visit. Participants recieved one single 0.5 mL dose of 13vPnC coadministered with Haemophilus Influenzae Type b (Hib) and Meningococcal C Vaccine (Menitorix) at the 12-month visit (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>Participants received one single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with meningococcal C-tetanus toxoid conjugate vaccine (NeisVac-C) and a combined diphtheria, tetanus, five component acellular pertussis (DT5aP), inactivated poliomyelitis (IPV) and haemophilus influenzae type b (Hib) conjugate vaccine (Pediacel) at the 2- and 4-month visits (infant series). Pediacel was administered without study vaccine at 3-month visit. Participants recieved one single 0.5 mL dose of 7vPnC coadministered with Haemophilus Influenzae Type b (Hib) and Meningococcal C Vaccine (Menitorix) at the 12-month visit (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Concentration of Pertusis Filamentous Haemagglutinin (FHA), Pertussis Toxoid (PT), Pertactin (PRN), and Fimbrial Agglutinogens (FIM) as Measured by ELISA in 13vPnC Group Relative to 7vPnC Group After the 2-dose Infant Series</title>
          <population>Evaluable immunogenicity (per protocol) population consisting of eligible participants who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations;(n) = number of participants with a determinate antibody concentration/titer for the specified concomitant antigen.</population>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pertussis FHA (n=119,113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.74" lower_limit="48.25" upper_limit="373.22"/>
                    <measurement group_id="O2" value="55.99" lower_limit="49.55" upper_limit="414.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis PT (n=119,112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.26" lower_limit="59.20" upper_limit="74.16"/>
                    <measurement group_id="O2" value="67.05" lower_limit="58.75" upper_limit="76.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis PRN (n=119,113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.33" lower_limit="51.78" upper_limit="72.65"/>
                    <measurement group_id="O2" value="61.07" lower_limit="52.31" upper_limit="71.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis FIM (n=119,113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.72" lower_limit="18.89" upper_limit="24.98"/>
                    <measurement group_id="O2" value="21.77" lower_limit="18.54" upper_limit="25.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Pertussis FHA the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for the concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Pertussis PT the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for the concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Pertussis PRN the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for the concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Pertussis FIM the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for the concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Antibody Concentration for Haemophilus Influenzae Type b PRP in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose.</title>
        <time_frame>one month after toddler dose (13 months of age)</time_frame>
        <population>Evaluable immunogenicity (per protocol) population of eligible participants who adhered to protocol requirements, had valid and determinate assay results, and had no other major protocol violations; (N) = number of participants with a determinate antibody concentration/titer to the specific concomitant antigen.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>Participants received one single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with meningococcal C-tetanus toxoid conjugate vaccine (NeisVac-C) and a combined diphtheria, tetanus, five component acellular pertussis (DT5aP), inactivated poliomyelitis (IPV) and haemophilus influenzae type b (Hib) conjugate vaccine (Pediacel) at the 2- and 4-month visits (infant series). Pediacel was administered without study vaccine at 3-month visit. Participants recieved one single 0.5 mL dose of 13vPnC coadministered with Haemophilus Influenzae Type b (Hib) and Meningococcal C Vaccine (Menitorix) at the 12-month visit (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>Participants received one single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with meningococcal C-tetanus toxoid conjugate vaccine (NeisVac-C) and a combined diphtheria, tetanus, five component acellular pertussis (DT5aP), inactivated poliomyelitis (IPV) and haemophilus influenzae type b (Hib) conjugate vaccine (Pediacel) at the 2- and 4-month visits (infant series). Pediacel was administered without study vaccine at 3-month visit. Participants recieved one single 0.5 mL dose of 7vPnC coadministered with Haemophilus Influenzae Type b (Hib) and Meningococcal C Vaccine (Menitorix) at the 12-month visit (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Concentration for Haemophilus Influenzae Type b PRP in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose.</title>
          <population>Evaluable immunogenicity (per protocol) population of eligible participants who adhered to protocol requirements, had valid and determinate assay results, and had no other major protocol violations; (N) = number of participants with a determinate antibody concentration/titer to the specific concomitant antigen.</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.22" lower_limit="17.66" upper_limit="27.96"/>
                    <measurement group_id="O2" value="19.75" lower_limit="16.05" upper_limit="24.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Haemophilus influenzae type b the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio</param_type>
            <param_value>1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.53</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants in the 13vPnC Group Achieving a Serotype-specific IgG Antibody Concentration ≥0.35 µg/mL Measured 1 Month After the 2-dose Infant Series, Before and After the Toddler Dose</title>
        <description>Percentages of participants achieving WHO predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
        <time_frame>one month after infant series dose 2 (5 months of age), before and after toddler dose (12 months of age)</time_frame>
        <population>Evaluable immunogenicity (per protocol) population consisting of eligible participants who adhered to protocol requirements, had valid and determinate assay results, and had no other major protocol violations; (n) = number of participants with a determinate igG antibody concentration to the given serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC After Infant Series Dose 2</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C at the 2- and 4-month visits, Pediacel at the 2-, 3-, and 4-month visits.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC Before Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C at the 2- and 4-month visits, Pediacel at the 2-, 3-, and 4-month visits.</description>
          </group>
          <group group_id="O3">
            <title>13vPnC After Toddler Dose</title>
            <description>Participants received Menitorix at the 12-month visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants in the 13vPnC Group Achieving a Serotype-specific IgG Antibody Concentration ≥0.35 µg/mL Measured 1 Month After the 2-dose Infant Series, Before and After the Toddler Dose</title>
          <description>Percentages of participants achieving WHO predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
          <population>Evaluable immunogenicity (per protocol) population consisting of eligible participants who adhered to protocol requirements, had valid and determinate assay results, and had no other major protocol violations; (n) = number of participants with a determinate igG antibody concentration to the given serotype.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common Serotypes - Serotype 4 (n=107,89,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.3" lower_limit="89.4" upper_limit="98.5"/>
                    <measurement group_id="O2" value="24.7" lower_limit="16.2" upper_limit="35.0"/>
                    <measurement group_id="O3" value="99.0" lower_limit="94.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 6B (n=107,86,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.2" lower_limit="30.8" upper_limit="50.1"/>
                    <measurement group_id="O2" value="74.4" lower_limit="63.9" upper_limit="83.2"/>
                    <measurement group_id="O3" value="98.0" lower_limit="93.1" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 9V (n=104,91,101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.6" lower_limit="77.3" upper_limit="91.7"/>
                    <measurement group_id="O2" value="44.0" lower_limit="33.6" upper_limit="54.8"/>
                    <measurement group_id="O3" value="98.0" lower_limit="93.0" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 14 (n=107,88,101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.5" lower_limit="85.8" upper_limit="96.7"/>
                    <measurement group_id="O2" value="92.0" lower_limit="84.3" upper_limit="96.7"/>
                    <measurement group_id="O3" value="100.0" lower_limit="96.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 18C (n=111,91,105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.8" lower_limit="86.3" upper_limit="96.8"/>
                    <measurement group_id="O2" value="13.2" lower_limit="7.0" upper_limit="21.9"/>
                    <measurement group_id="O3" value="97.1" lower_limit="91.9" upper_limit="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 19F (n=109,91,104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.6" lower_limit="87.2" upper_limit="97.4"/>
                    <measurement group_id="O2" value="67.0" lower_limit="56.4" upper_limit="76.5"/>
                    <measurement group_id="O3" value="98.1" lower_limit="93.2" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 23F (n=111,89,104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7" lower_limit="57.1" upper_limit="75.3"/>
                    <measurement group_id="O2" value="37.1" lower_limit="27.1" upper_limit="48.0"/>
                    <measurement group_id="O3" value="98.1" lower_limit="93.2" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 1 (n=107,88,101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.2" lower_limit="92.0" upper_limit="99.4"/>
                    <measurement group_id="O2" value="50.0" lower_limit="39.1" upper_limit="60.9"/>
                    <measurement group_id="O3" value="100.0" lower_limit="96.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 3 (n=107,87,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.0" lower_limit="77.9" upper_limit="91.9"/>
                    <measurement group_id="O2" value="12.6" lower_limit="6.5" upper_limit="21.5"/>
                    <measurement group_id="O3" value="88.2" lower_limit="80.4" upper_limit="93.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 5 (n=103,88,101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.3" lower_limit="81.7" upper_limit="94.5"/>
                    <measurement group_id="O2" value="78.4" lower_limit="68.4" upper_limit="86.5"/>
                    <measurement group_id="O3" value="100.0" lower_limit="96.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 6A (n=106,86,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.2" lower_limit="70.3" upper_limit="86.5"/>
                    <measurement group_id="O2" value="79.1" lower_limit="69.0" upper_limit="87.1"/>
                    <measurement group_id="O3" value="98.0" lower_limit="92.9" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 7F (n=107,91,100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.4" lower_limit="88.2" upper_limit="97.9"/>
                    <measurement group_id="O2" value="71.4" lower_limit="61.0" upper_limit="80.4"/>
                    <measurement group_id="O3" value="100.0" lower_limit="96.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 19A (n=110,91,103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.7" lower_limit="86.2" upper_limit="96.8"/>
                    <measurement group_id="O2" value="86.8" lower_limit="78.1" upper_limit="93.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="96.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Antibody Concentration in 13vPnC Group After the 2-dose Infant Series, Before and After the Toddler Dose.</title>
        <description>Antibody concentration/geometric mean concentration (GMC) as measured by ELISA for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented with corresponding 2-sided 95% CI.</description>
        <time_frame>one month after infant series dose 2 (5 months of age) and before and after toddler dose (12 months of age)</time_frame>
        <population>Evaluable immunogenicity (per protocol) population consisting of eligible participants who adhered to protocol requirements, had valid and determinate assay results, and had no other major protocol violations; (n) = number of participants with a determinate antibody concentration for the specified serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC After Infant Series Dose 2</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C at the 2- and 4-month visits, Pediacel at the 2-, 3-, and 4-month visits, and Menitorix at the 12-month visit.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC Before Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C at the 2- and 4-month visits, Pediacel at the 2-, 3-, and 4-month visits, and Menitorix at the 12-month visit.</description>
          </group>
          <group group_id="O3">
            <title>13vPnC After Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C at the 2- and 4-month visits, Pediacel at the 2-, 3-, and 4-month visits, and Menitorix at the 12-month visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Concentration in 13vPnC Group After the 2-dose Infant Series, Before and After the Toddler Dose.</title>
          <description>Antibody concentration/geometric mean concentration (GMC) as measured by ELISA for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented with corresponding 2-sided 95% CI.</description>
          <population>Evaluable immunogenicity (per protocol) population consisting of eligible participants who adhered to protocol requirements, had valid and determinate assay results, and had no other major protocol violations; (n) = number of participants with a determinate antibody concentration for the specified serotype.</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common Serotypes - Serotype 4 (n=107,87,87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.37" lower_limit="1.16" upper_limit="1.62"/>
                    <measurement group_id="O2" value="0.21" lower_limit="0.17" upper_limit="0.24"/>
                    <measurement group_id="O3" value="3.52" lower_limit="2.91" upper_limit="4.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 6B (n=107,85,85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" lower_limit="0.21" upper_limit="0.33"/>
                    <measurement group_id="O2" value="0.77" lower_limit="0.60" upper_limit="0.99"/>
                    <measurement group_id="O3" value="7.67" lower_limit="5.88" upper_limit="10.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 9V (n=104,88,88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87" lower_limit="0.72" upper_limit="1.05"/>
                    <measurement group_id="O2" value="0.29" lower_limit="0.24" upper_limit="0.36"/>
                    <measurement group_id="O3" value="2.46" lower_limit="2.03" upper_limit="2.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 14 (n=107,87,87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83" lower_limit="1.47" upper_limit="2.27"/>
                    <measurement group_id="O2" value="1.34" lower_limit="1.09" upper_limit="1.66"/>
                    <measurement group_id="O3" value="11.32" lower_limit="9.27" upper_limit="13.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 18C (n=111,91,91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.37" lower_limit="1.14" upper_limit="1.64"/>
                    <measurement group_id="O2" value="0.20" lower_limit="0.17" upper_limit="0.23"/>
                    <measurement group_id="O3" value="2.14" lower_limit="1.82" upper_limit="2.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 19F (n=109,90,90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.38" lower_limit="1.88" upper_limit="3.01"/>
                    <measurement group_id="O2" value="0.60" lower_limit="0.46" upper_limit="0.79"/>
                    <measurement group_id="O3" value="7.25" lower_limit="5.65" upper_limit="9.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 23F (n=111,88,88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" lower_limit="0.42" upper_limit="0.67"/>
                    <measurement group_id="O2" value="0.24" lower_limit="0.19" upper_limit="0.32"/>
                    <measurement group_id="O3" value="3.13" lower_limit="2.59" upper_limit="3.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 1 (n=107,85,85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" lower_limit="1.41" upper_limit="2.04"/>
                    <measurement group_id="O2" value="0.39" lower_limit="0.33" upper_limit="0.46"/>
                    <measurement group_id="O3" value="5.60" lower_limit="4.60" upper_limit="6.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 3 (n=107,85,85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" lower_limit="0.56" upper_limit="0.71"/>
                    <measurement group_id="O2" value="0.14" lower_limit="0.10" upper_limit="0.18"/>
                    <measurement group_id="O3" value="0.98" lower_limit="0.78" upper_limit="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 5 (n=103,86,86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" lower_limit="0.79" upper_limit="1.14"/>
                    <measurement group_id="O2" value="0.59" lower_limit="0.49" upper_limit="0.72"/>
                    <measurement group_id="O3" value="3.68" lower_limit="3.04" upper_limit="4.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 6A (n=106,83,83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.86" lower_limit="0.68" upper_limit="1.07"/>
                    <measurement group_id="O2" value="0.81" lower_limit="0.64" upper_limit="1.03"/>
                    <measurement group_id="O3" value="6.31" lower_limit="5.06" upper_limit="7.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 7F (n=107,87,87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.14" lower_limit="1.75" upper_limit="2.62"/>
                    <measurement group_id="O2" value="0.56" lower_limit="0.48" upper_limit="0.66"/>
                    <measurement group_id="O3" value="4.06" lower_limit="3.42" upper_limit="4.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 19A (n=110,89,89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.90" lower_limit="1.54" upper_limit="2.34"/>
                    <measurement group_id="O2" value="1.01" lower_limit="0.77" upper_limit="1.32"/>
                    <measurement group_id="O3" value="11.33" lower_limit="9.29" upper_limit="13.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-Specified Local Reactions</title>
        <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Participants may be represented in more than 1 category.</description>
        <time_frame>During the 4-day period after each dose</time_frame>
        <population>The safety population included all participants who received at least 1 dose of vaccine; (n)= number of participants reporting yes for at least 1 day or no for all days.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Dose 1</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and Pediacel at 2 months of age.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC Dose 1</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with NeisVac-C and Pediacel at 2 months of age.</description>
          </group>
          <group group_id="O3">
            <title>13vPnC Dose 2</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and Pediacel at 4 months of age.</description>
          </group>
          <group group_id="O4">
            <title>7vPnC Dose 2</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with NeisVac-C and Pediacel at 4 months of age.</description>
          </group>
          <group group_id="O5">
            <title>13vPnC Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with Menitorix at 12 months of age.</description>
          </group>
          <group group_id="O6">
            <title>7vPnC Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with Menitorix at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-Specified Local Reactions</title>
          <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Participants may be represented in more than 1 category.</description>
          <population>The safety population included all participants who received at least 1 dose of vaccine; (n)= number of participants reporting yes for at least 1 day or no for all days.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="139"/>
                <count group_id="O3" value="136"/>
                <count group_id="O4" value="135"/>
                <count group_id="O5" value="131"/>
                <count group_id="O6" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tenderness-Any (n=123,127,114,96,87,71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.7"/>
                    <measurement group_id="O2" value="43.3"/>
                    <measurement group_id="O3" value="42.1"/>
                    <measurement group_id="O4" value="40.6"/>
                    <measurement group_id="O5" value="44.8"/>
                    <measurement group_id="O6" value="50.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness-Significant (n=116,122,97,89,77,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="6.6"/>
                    <measurement group_id="O3" value="4.1"/>
                    <measurement group_id="O4" value="4.5"/>
                    <measurement group_id="O5" value="3.9"/>
                    <measurement group_id="O6" value="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling-Any (n=121,126,106,93,83,68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.8"/>
                    <measurement group_id="O2" value="29.4"/>
                    <measurement group_id="O3" value="30.2"/>
                    <measurement group_id="O4" value="34.4"/>
                    <measurement group_id="O5" value="30.1"/>
                    <measurement group_id="O6" value="39.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling-Mild (n=120,125,105,93,82,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.7"/>
                    <measurement group_id="O2" value="27.2"/>
                    <measurement group_id="O3" value="28.6"/>
                    <measurement group_id="O4" value="29.0"/>
                    <measurement group_id="O5" value="28.0"/>
                    <measurement group_id="O6" value="34.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling-Moderate (n=118,121,98,88,77,60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8"/>
                    <measurement group_id="O2" value="6.6"/>
                    <measurement group_id="O3" value="8.2"/>
                    <measurement group_id="O4" value="6.8"/>
                    <measurement group_id="O5" value="3.9"/>
                    <measurement group_id="O6" value="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling-Severe (n=115,119,96,88,76,57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="1.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness-Any (n=122,126,107,99,85,73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.1"/>
                    <measurement group_id="O2" value="39.7"/>
                    <measurement group_id="O3" value="39.3"/>
                    <measurement group_id="O4" value="40.4"/>
                    <measurement group_id="O5" value="38.8"/>
                    <measurement group_id="O6" value="53.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness-Mild (n=122,126,106,99,83,71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3"/>
                    <measurement group_id="O2" value="39.7"/>
                    <measurement group_id="O3" value="37.7"/>
                    <measurement group_id="O4" value="37.4"/>
                    <measurement group_id="O5" value="33.7"/>
                    <measurement group_id="O6" value="49.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness-Moderate (n=116,119,98,88,78,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="4.1"/>
                    <measurement group_id="O4" value="3.4"/>
                    <measurement group_id="O5" value="12.8"/>
                    <measurement group_id="O6" value="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness-Severe (n=115,119,97,88,76,57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="2.1"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-Specified Systemic Events</title>
        <description>Systemic events (fever ≥ 38 degrees Celsius [C] but ≤ 39 C, fever &gt;39 C but ≤ 40 C, fever &gt; 40 C, decreased appetite, irritability, increased sleep, decreased sleep, use of medication (Meds) to prevent symptoms, and use of medication to treat symptoms) were collected using an electronic diary; percentage of participants with each event was evaluated.</description>
        <time_frame>During the 4-day period after each dose</time_frame>
        <population>Safety population included all participants who received at least 1 dose of vaccine; (n) = number of participants reporting yes for at least 1 day or no for all days.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Dose 1</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and Pediacel at 2 months of age.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC Dose 1</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with NeisVac-C and Pediacel at 2 months of age.</description>
          </group>
          <group group_id="O3">
            <title>13vPnC Dose 2</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with NeisVac-C and Pediacel at 4 months of age.</description>
          </group>
          <group group_id="O4">
            <title>7vPnC Dose 2</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with NeisVac-C and Pediacel at 4 months of age.</description>
          </group>
          <group group_id="O5">
            <title>13vPnC Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with Menitorix at 12 months of age.</description>
          </group>
          <group group_id="O6">
            <title>7vPnC Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with Menitorix at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-Specified Systemic Events</title>
          <description>Systemic events (fever ≥ 38 degrees Celsius [C] but ≤ 39 C, fever &gt;39 C but ≤ 40 C, fever &gt; 40 C, decreased appetite, irritability, increased sleep, decreased sleep, use of medication (Meds) to prevent symptoms, and use of medication to treat symptoms) were collected using an electronic diary; percentage of participants with each event was evaluated.</description>
          <population>Safety population included all participants who received at least 1 dose of vaccine; (n) = number of participants reporting yes for at least 1 day or no for all days.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="139"/>
                <count group_id="O3" value="136"/>
                <count group_id="O4" value="135"/>
                <count group_id="O5" value="131"/>
                <count group_id="O6" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever ≥38°C but ≤39°C (n=116,119,96,88,78,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0"/>
                    <measurement group_id="O2" value="3.4"/>
                    <measurement group_id="O3" value="3.1"/>
                    <measurement group_id="O4" value="4.5"/>
                    <measurement group_id="O5" value="7.7"/>
                    <measurement group_id="O6" value="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;39°C but ≤40°C (n=115,119,95,88,76,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;40°C (n=115,119,96,88,76,57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="2.1"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite (n=120,129,104,98,92,68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.2"/>
                    <measurement group_id="O2" value="34.1"/>
                    <measurement group_id="O3" value="35.6"/>
                    <measurement group_id="O4" value="37.8"/>
                    <measurement group_id="O5" value="39.1"/>
                    <measurement group_id="O6" value="44.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (n=128,135,117,119,97,80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.6"/>
                    <measurement group_id="O2" value="74.1"/>
                    <measurement group_id="O3" value="71.8"/>
                    <measurement group_id="O4" value="80.7"/>
                    <measurement group_id="O5" value="74.2"/>
                    <measurement group_id="O6" value="76.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased sleep (n=129,129,114,109,88,71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.8"/>
                    <measurement group_id="O2" value="66.7"/>
                    <measurement group_id="O3" value="51.8"/>
                    <measurement group_id="O4" value="56.9"/>
                    <measurement group_id="O5" value="38.6"/>
                    <measurement group_id="O6" value="40.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased sleep (n=119,124,98,100,81,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.8"/>
                    <measurement group_id="O2" value="33.9"/>
                    <measurement group_id="O3" value="35.7"/>
                    <measurement group_id="O4" value="38.0"/>
                    <measurement group_id="O5" value="32.1"/>
                    <measurement group_id="O6" value="44.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meds to treat symptoms (n=123,128,108,110,85,72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.9"/>
                    <measurement group_id="O2" value="40.6"/>
                    <measurement group_id="O3" value="50.9"/>
                    <measurement group_id="O4" value="54.5"/>
                    <measurement group_id="O5" value="49.4"/>
                    <measurement group_id="O6" value="58.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meds to prevent symptoms (n=122,124,117,103,92,77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.2"/>
                    <measurement group_id="O2" value="40.3"/>
                    <measurement group_id="O3" value="48.7"/>
                    <measurement group_id="O4" value="50.5"/>
                    <measurement group_id="O5" value="52.2"/>
                    <measurement group_id="O6" value="67.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titer (GMT) of Meningococcal C Antigen as Measured by SBA in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose</title>
        <time_frame>one month after toddler dose (13 months of age)</time_frame>
        <population>Evaluable immunogenicity (per protocol) population consisting of eligible participants who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations;(N)= number of participants with a determinate antibody concentration/titer for the specified concomitant antigen.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>Participants received one single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with meningococcal C-tetanus toxoid conjugate vaccine (NeisVac-C) and a combined diphtheria, tetanus, five component acellular pertussis (DT5aP), inactivated poliomyelitis (IPV) and haemophilus influenzae type b (Hib) conjugate vaccine (Pediacel) at the 2- and 4-month visits (infant series). Pediacel was administered without study vaccine at 3-month visit. Participants recieved one single 0.5 mL dose of 13vPnC coadministered with Haemophilus Influenzae Type b (Hib) and Meningococcal C Vaccine (Menitorix) at the 12-month visit (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>Participants received one single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with meningococcal C-tetanus toxoid conjugate vaccine (NeisVac-C) and a combined diphtheria, tetanus, five component acellular pertussis (DT5aP), inactivated poliomyelitis (IPV) and haemophilus influenzae type b (Hib) conjugate vaccine (Pediacel) at the 2- and 4-month visits (infant series). Pediacel was administered without study vaccine at 3-month visit. Participants recieved one single 0.5 mL dose of 7vPnC coadministered with Haemophilus Influenzae Type b (Hib) and Meningococcal C Vaccine (Menitorix) at the 12-month visit (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) of Meningococcal C Antigen as Measured by SBA in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose</title>
          <population>Evaluable immunogenicity (per protocol) population consisting of eligible participants who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations;(N)= number of participants with a determinate antibody concentration/titer for the specified concomitant antigen.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="656.11" lower_limit="445.46" upper_limit="966.38"/>
                    <measurement group_id="O2" value="771.67" lower_limit="509.98" upper_limit="1167.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Meningococcal C the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ration</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.48</ci_lower_limit>
            <ci_upper_limit>1.49</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>13vPnC Infant Series</title>
          <description>Participants received one single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with meningococcal C-tetanus toxoid conjugate vaccine (NeisVac-C) and a combined diphtheria, tetanus, five component acellular pertussis (DT5aP), inactivated poliomyelitis (IPV) and haemophilus influenzae type b (Hib) conjugate vaccine (Pediacel) at the 2- and 4-month visits. Pediacel was administered without study vaccine at 3-month visit.</description>
        </group>
        <group group_id="E2">
          <title>7vPnC Infant Series</title>
          <description>Participants received one single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with meningococcal C-tetanus toxoid conjugate vaccine (NeisVac-C) and a combined diphtheria, tetanus, five component acellular pertussis (DT5aP), inactivated poliomyelitis (IPV) and haemophilus influenzae type b (Hib) conjugate vaccine (Pediacel) at the 2- and 4-month visits. Pediacel was administered without study vaccine at 3-month visit.</description>
        </group>
        <group group_id="E3">
          <title>13vPnC Post-Infant Series</title>
          <description>Participants received one single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with meningococcal C-tetanus toxoid conjugate vaccine (NeisVac-C) and a combined diphtheria, tetanus, five component acellular pertussis (DT5aP), inactivated poliomyelitis (IPV) and haemophilus influenzae type b (Hib) conjugate vaccine (Pediacel) at the 2- and 4-month visits (assessment at 5 months of age, 1 month after the infant series). Pediacel was administered without study vaccine at 3-month visit.</description>
        </group>
        <group group_id="E4">
          <title>7vPnC Post-Infant Series</title>
          <description>Participants received one single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with meningococcal C-tetanus toxoid conjugate vaccine (NeisVac-C) and a combined diphtheria, tetanus, five component acellular pertussis (DT5aP), inactivated poliomyelitis (IPV) and haemophilus influenzae type b (Hib) conjugate vaccine (Pediacel) at the 2- and 4-month visits (assessment at 5 months of age, 1 month after the infant series). Pediacel was administered without study vaccine at 3-month visit.</description>
        </group>
        <group group_id="E5">
          <title>13vPnC Toddler Series</title>
          <description>Participants recieved one single 0.5 mL dose of 13vPnC coadministered with Haemophilus Influenzae Type b (Hib) and Meningococcal C Vaccine (Menitorix) at the 12-month visit (toddler dose).</description>
        </group>
        <group group_id="E6">
          <title>7vPnC Toddler Series</title>
          <description>Participants recieved one single 0.5 mL dose of 7vPnC coadministered with Haemophilus Influenzae Type b (Hib) and Meningococcal C Vaccine (Menitorix) at the 12-month visit (toddler dose).</description>
        </group>
        <group group_id="E7">
          <title>13vPnC 6-Month Follow-up</title>
          <description>Participants recieved one single 0.5 mL dose of 13vPnC coadministered with Haemophilus Influenzae Type b (Hib) &amp; Meningococcal C Vaccine (Menitorix) at the 12-month visit (assessment at 18 months of age, 6 months after the toddler dose).</description>
        </group>
        <group group_id="E8">
          <title>7vPnC 6-Month Follow-up</title>
          <description>Participants recieved one single 0.5 mL dose of 7vPnC coadministered with Haemophilus Influenzae Type b (Hib) and Meningococcal C Vaccine (Menitorix) at the 12-month visit(assessment at 18 months of age, 6 months after the toddler dose).</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrooesophaegeal reflux</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Mastoiditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Tongue injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Hemiplegia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Breath holding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Local Reactions</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="111" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="105" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="72" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="61" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cyanosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Dacryostenosis congenital</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Lymphangioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Cerumen impaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Tympanic membrane perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Eye discharge</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Astigmatism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Dacryostenosis acquired</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Hypermetropia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Teething</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Infantile spitting up</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Stomach discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Frequent bowel movements</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Reflux oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever ≥38°C but ≤39°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Fever ≥38 degrees C but ≤39 degrees C</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="61"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever ≥38°C but ≤39°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Fever ≥38 degrees C but ≤39 degrees C</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;39°C but ≤40°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Fever &gt;39 degrees C but ≤40 degrees C</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;39°C but ≤40°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Fever &gt;39 degrees C but ≤40 degrees</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;40°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Fever &gt;40 degrees C</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;40°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Fever &gt;40 degrees C</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Decreased appetite</description>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="36" subjects_at_risk="92"/>
                <counts group_id="E6" subjects_affected="30" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Decreased appetite</description>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Irritability</description>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="72" subjects_at_risk="97"/>
                <counts group_id="E6" subjects_affected="61" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Irritability</description>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="96" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Increased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Increased sleep</description>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="34" subjects_at_risk="88"/>
                <counts group_id="E6" subjects_affected="29" subjects_at_risk="71"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Increased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Increased sleep</description>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Decreased sleep</description>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="81"/>
                <counts group_id="E6" subjects_affected="30" subjects_at_risk="67"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Decreased sleep</description>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Injection site infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Viral skin infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Eczema infected</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Dermatitis infected</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Skin candida</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Rubella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Physical examination abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Weight gain poor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Lactose intolerance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>High-pitched crying</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Hypertonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Staring</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Grunting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Eczema infantile</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Heat rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Skin discolouration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Umbilical erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Tenderness (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Tenderness (any)=present at site of vaccination.</description>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="39" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="36" subjects_at_risk="71"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Tenderness (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Tenderness (any)</description>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Tenderness (Significant)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Tenderness (significant)=present and interfered with limb movement.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Tenderness (Significant)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Tenderness (significant)</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Induration (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Induration (any)=present at site of vaccination.</description>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="27" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Induration (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Induration (Any)</description>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Induration (mild)=0.5 centimeters (cm) to 2.0 cm.</description>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="82"/>
                <counts group_id="E6" subjects_affected="23" subjects_at_risk="66"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Induration (Mild)</description>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Induration (Moderate)=2.5 cm to 7.0 cm.</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="121"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Induration (moderate)</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Induration (severe) &gt;7.0 cm.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Induration (severe)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Erythema (any)=present at site of vaccination.</description>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="33" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="39" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Erythema (any)</description>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Erythema (mild)=0.5 cm to 2.0 cm.</description>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="35" subjects_at_risk="71"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Erythema (mild)</description>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Erythema (moderate)=2.5 cm to 7.0 cm.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="61"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Erythema (moderate)</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Erythema (severe) &gt;7.0 cm.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Erythema (severe)</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

